(AMRN) Amarin - Overview
Stock: Omega-3, Cardiovascular, Prescription, Triglyceride, Vascepa
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 67.5% |
| Relative Tail Risk | -19.1% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.65 |
| Alpha | 15.08 |
| Character TTM | |
|---|---|
| Beta | 0.884 |
| Beta Downside | 0.858 |
| Drawdowns 3y | |
|---|---|
| Max DD | 80.58% |
| CAGR/Max DD | -0.34 |
Description: AMRN Amarin December 29, 2025
Amarin Corporation plc (NASDAQ: AMRN) is a Dublin-based biopharma that develops and commercializes cardiovascular therapeutics, most notably VASCEPA® (icosapent ethyl), a prescription-only omega-3 fatty-acid drug used to lower triglycerides in patients with severe hypertriglyceridemia. The company distributes primarily through wholesale and specialty-pharmacy channels in the United States, Europe, and other international markets, and it maintains a development partnership with Japan’s Mochida Pharmaceutical to explore additional EPA-based indications.
Key recent metrics: FY 2023 VASCEPA net sales fell to roughly $1.0 billion, reflecting the loss of Medicare Part D coverage for the cardiovascular-risk reduction indication in 2022; however, a 2023 FDA label expansion reinstated the drug’s use for secondary prevention, which could re-ignite demand. The global prescription omega-3 market is projected to grow at a CAGR of ~5 % through 2028, driven by an aging population and rising prevalence of metabolic syndrome, while reimbursement uncertainty remains a primary headwind for Amarin’s revenue outlook.
For a data-driven assessment of AMRN’s valuation and risk profile, you may find the analytics on ValueRay worth a quick look.
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income: -86.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.03 > 0.02 and ΔFCF/TA -0.86 > 1.0 |
| NWC/Revenue: 197.7% < 20% (prev 185.6%; Δ 12.13% < -1%) |
| CFO/TA -0.03 > 3% & CFO -21.9m > Net Income -86.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.45 > 1.5 & < 3 |
| Outstanding Shares: last quarter (415.5m) vs 12m ago 1.07% < -2% |
| Gross Margin: 39.06% > 18% (prev 0.56%; Δ 3850 % > 0.5%) |
| Asset Turnover: 31.99% > 50% (prev 32.21%; Δ -0.21% > 0%) |
| Interest Coverage Ratio: -7894 > 6 (EBITDA TTM -52.2m / Interest Expense TTM 7000 ) |
Altman Z'' -11.82
| A: 0.68 (Total Current Assets 628.3m - Total Current Liabilities 182.2m) / Total Assets 659.8m |
| B: -2.59 (Retained Earnings -1.71b / Total Assets 659.8m) |
| C: -0.08 (EBIT TTM -55.3m / Avg Total Assets 705.2m) |
| D: -6.95 (Book Value of Equity -1.40b / Total Liabilities 200.9m) |
| Altman-Z'' Score: -11.82 = D |
Beneish M -3.03
| DSRI: 1.21 (Receivables 127.3m/112.6m, Revenue 225.6m/241.7m) |
| GMI: 1.43 (GM 39.06% / 55.85%) |
| AQI: 0.30 (AQ_t 0.04 / AQ_t-1 0.12) |
| SGI: 0.93 (Revenue 225.6m / 241.7m) |
| TATA: -0.10 (NI -86.2m - CFO -21.9m) / TA 659.8m) |
| Beneish M-Score: -3.03 (Cap -4..+1) = AA |
What is the price of AMRN shares?
Over the past week, the price has changed by -1.14%, over one month by +7.74%, over three months by -5.87% and over the past year by +29.39%.
Is AMRN a buy, sell or hold?
- StrongBuy: 0
- Buy: 0
- Hold: 1
- Sell: 2
- StrongSell: 0
What are the forecasts/targets for the AMRN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 12 | -18.6% |
| Analysts Target Price | 12 | -18.6% |
| ValueRay Target Price | 12.4 | -16% |
AMRN Fundamental Data Overview February 02, 2026
P/S = 1.3682
P/B = 0.671
P/EG = -1.74
Revenue TTM = 225.6m USD
EBIT TTM = -55.3m USD
EBITDA TTM = -52.2m USD
Long Term Debt = 6.73m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = unknown (none)
Debt = 6.73m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -116.1m USD (from netDebt column, last quarter)
Enterprise Value = 30.4m USD (310.2m + Debt 6.73m - CCE 286.6m)
Interest Coverage Ratio = -7894 (Ebit TTM -55.3m / Interest Expense TTM 7000 )
EV/FCF = -1.39x (Enterprise Value 30.4m / FCF TTM -21.9m)
FCF Yield = -71.98% (FCF TTM -21.9m / Enterprise Value 30.4m)
FCF Margin = -9.69% (FCF TTM -21.9m / Revenue TTM 225.6m)
Net Margin = -38.20% (Net Income TTM -86.2m / Revenue TTM 225.6m)
Gross Margin = 39.06% ((Revenue TTM 225.6m - Cost of Revenue TTM 137.5m) / Revenue TTM)
Gross Margin QoQ = 45.73% (prev 69.23%)
Tobins Q-Ratio = 0.05 (Enterprise Value 30.4m / Total Assets 659.8m)
Interest Expense / Debt = 0.10% (Interest Expense 7000 / Debt 6.73m)
Taxrate = 21.0% (US default 21%)
NOPAT = -43.7m (EBIT -55.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.45 (Total Current Assets 628.3m / Total Current Liabilities 182.2m)
Debt / Equity = 0.01 (Debt 6.73m / totalStockholderEquity, last quarter 458.9m)
Debt / EBITDA = 2.22 (negative EBITDA) (Net Debt -116.1m / EBITDA -52.2m)
Debt / FCF = 5.31 (negative FCF - burning cash) (Net Debt -116.1m / FCF TTM -21.9m)
Total Stockholder Equity = 470.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -12.22% (Net Income -86.2m / Total Assets 659.8m)
RoE = -18.30% (Net Income TTM -86.2m / Total Stockholder Equity 470.9m)
RoCE = -11.57% (EBIT -55.3m / Capital Employed (Equity 470.9m + L.T.Debt 6.73m))
RoIC = -9.27% (negative operating profit) (NOPAT -43.7m / Invested Capital 470.9m)
WACC = 8.98% (E(310.2m)/V(317.0m) * Re(9.17%) + D(6.73m)/V(317.0m) * Rd(0.10%) * (1-Tc(0.21)))
Discount Rate = 9.17% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.86%
Fair Price DCF = unknown (Cash Flow -21.9m)
EPS Correlation: -49.76 | EPS CAGR: -71.52% | SUE: 1.77 | # QB: 2
Revenue Correlation: -83.95 | Revenue CAGR: -25.23% | SUE: 0.46 | # QB: 0
EPS next Year (2026-12-31): EPS=0.59 | Chg30d=+0.440 | Revisions Net=+1 | Growth EPS=+168.2% | Growth Revenue=-18.7%